The currents swirling around the steep price increases on Mylan NV’s (NASDAQ:MYL) lifesaving EpiPen drug just got a little deeper for the company’s embattled CEO. When the company’s chief executive Heather Bresch testified before a congressional committee last week, it was claimed that Mylan’s profit on a $ 608 two-pack of the injectors was just $ 100. […]
Corporate News – The Cerbat Gem
Wednesday, January 25, 2017
Mylan Under Fire For Creative Accounting Of EpiPen Profits
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment